Skip to main content
. 2024 Aug 12;7(8):e2427258. doi: 10.1001/jamanetworkopen.2024.27258

Table 2. Comparison of Tirzepatide vs GLP-1 RA for Primary and Secondary Outcomes.

Outcome No. of patients with outcome AHR (95% CI) P value E-value (E-value for the upper limit of CI)
Tirzepatide (n = 14 832) GLP-1 RA (n = 14 832)
Primary outcome
All-cause mortality 95 166 0.58 (0.45-0.75)a <.001b 2.82 (1.99)
Secondary outcomes
MACEs 472 589 0.80 (0.71-0.91)a <.001b 1.79 (1.44)
MACE and all-cause mortality 543 721 0.76 (0.68-0.84)a <.001b 1.98 (1.65)
Kidney events 53 102 0.52 (0.37-0.73)a <.001b 3.24 (2.09)
Acute kidney injury 506 652 0.78 (0.70-0.88)a <.001b 1.87 (1.53)
MAKEs 129 241 0.54 (0.44-0.67)a <.001b 3.11 (2.35)

Abbreviations: AHR, adjusted hazard ratio; GLP-1 RA, glucagon-like peptide 1 receptor agonist; MACE, major adverse cardiovascular event; MAKE, major adverse kidney event.

a

Proportionality (Schoenfeld test P > .05).

b

Bonferroni-corrected α = .0083.